Weight Loss Drugs Contributing to Decline in U.S. Obesity Rates

The U.S. adult obesity rate has decreased from 39.9% in 2022 to 37.0% in 2025, partly due to increased use of GLP-1 weight loss drugs like semaglutide, which has more than doubled in usage since early 2024. Despite the decline in obesity, diabetes diagnoses have reached a record high, indicating that weight loss alone may not reduce the prevalence of diabetes. The trend suggests that medical treatments, combined with healthier habits, could influence future health outcomes, but the high rates of obesity and diabetes remain significant public health challenges.